Article
Oncology
Weiting Li, Klaas Kok, Geok Wee Tan, Pei Meng, Mirjam Mastik, Naomi Rifaela, Frank Scherpen, T. Jeroen N. Hiltermann, Harry J. M. Groen, Anthonie J. van der Wekken, Anke van den Berg
Summary: Treatment outcomes for NSCLC patients have significantly improved with the introduction of TKI, but resistance mutations such as EGFR T790M remain a challenge. Pre-treatment detection of T790M mutations in tissue samples is rare, even in patients who later develop resistance. Screening for T790M mutations in pre-treatment samples can provide crucial information for the effective management of NSCLC patients with EGFR mutations.
Article
Oncology
Kentaro Tanaka, Hajime Asahina, Junji Kishimoto, Yoshihiro Miyata, Takahiro Uchida, Kana Watanabe, Kosuke Hamai, Taishi Harada, Yukari Tsubata, Shunichi Sugawara, Kunihiko Kobayashi, Kenji Sugio, Satoshi Oizumi, Isamu Okamoto
Summary: The study investigated the combination of osimertinib with cytotoxic chemotherapy for EGFR-mutated NSCLC patients, finding that adding chemotherapy as a second-line treatment did not prolong survival but was generally well-tolerated.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guerin, Laurent Dano, Valerie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Celine Mascaux, Michele Beau-Faller
Summary: Non-small cell lung cancer (NSCLC) is the most common cancer in the world. Activating EGFR gene mutations are predictive for the efficacy of EGFR tyrosine kinase inhibitors (TKIs). Acquired resistance is a challenge, leading to the search for novel biomarkers and drug targets that vary among different generations/lines of EGFR TKIs.
Article
Oncology
Yvonne L. E. Ang, Xiaotian Zhao, Thanyanan Reungwetwattana, Byoung-Chul Cho, Bin-Chi Liao, Rebecca Yeung, Herbert H. Loong, Dong-Wan Kim, James Chih-Hsin Yang, Sun Min Lim, Myung-Ju Ahn, Se-Hoon Lee, Thitiporn Suwatanapongched, Kanchaporn Kongchauy, Qiuxiang Ou, Ruoying Yu, Bee Choo Tai, Boon Cher Goh, Tony S. K. Mok, Ross A. Soo
Summary: Non-invasive blood testing for T790M mutation can guide the treatment of lung cancers with EGFR gene mutations using Osimertinib, and has good outcomes. Levels of DNA markers in the blood can predict treatment outcomes.
Article
Oncology
Li Ma, Haoyang Li, Dongpo Wang, Ying Hu, Mengjun Yu, Quan Zhang, Na Qin, Xinyong Zhang, Xi Li, Hui Zhang, Yuhua Wu, Jialin Lv, Xinjie Yang, Ruoying Yu, Shucai Zhang, Jinghui Wang
Summary: Dynamic cfDNA analysis using NGS can predict efficacy and resistance mechanisms of third-generation EGFR TKIs in NSCLC patients. Clearance of cfDNA and T790M level are significantly associated with clinical outcomes. The most common resistant mutation of third-generation TKIs is EGFR C797S.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Go Naka, Takuma Yokoyama, Kazuhiro Usui, Hiroo Ishida, Kazuma Kishi, Kohei Uemura, Yasuo Ohashi, Hideo Kunitoh
Summary: In this study, we found no significant difference in progression-free survival between plasma ctDNA-positive and ctDNA-negative groups. Additionally, osimertinib showed efficacy in the treatment of NSCLC patients with T790M mutation.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Xing-mei Liang, Qiong Qin, Bo-ning Liu, Xiao-qing Li, Li-li Zeng, Jing Wang, Ling-ping Kong, Dian-sheng Zhong, Lin-lin Sun
Summary: The study reveals that DNA damage repair capacity is compromised in osimertinib-resistant cells, and inhibiting DNA-PK can increase sensitivity to osimertinib. Combination of osimertinib with DNA-PK inhibitors synergistically suppresses proliferation of resistant cells.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Oncology
Kazuko Sakai, Takayuki Takahama, Mototsugu Shimokawa, Koichi Azuma, Masayuki Takeda, Terufumi Kato, Haruko Daga, Isamu Okamoto, Hiroaki Akamatsu, Shunsuke Teraoka, Akira Ono, Tatsuo Ohira, Toshihide Yokoyama, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Kazuto Nishio
Summary: The WJOG8815L phase II clinical study examined the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA from NSCLC patients receiving osimertinib treatment. Results showed a decrease in sensitizing and T790M-EGFR mutant fractions during treatment, with a rebound of sensitizing EGFR MF observed at disease progression or treatment discontinuation. Significant differences in response rates and progression-free survival were observed based on sensitizing EGFR MF grouping at cycle 4.
MOLECULAR ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Hsiang-Ling Ho, Fang-Yu Wang, Chi-Lu Chiang, Chun-Ming Tsai, Chao-Hua Chiu, Teh-Ying Chou
Summary: The dynamic monitoring of tissue and plasma EGFR mutation status using ddPCR has a clinical impact on the evaluation of treatment efficacy, patient outcomes, and resistance emergence in NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Shiqi Ma, Lu Zhang, Yuan Ren, Wei Dai, Tingqing Chen, Liping Luo, Juan Zeng, Kun Mi, Jinyi Lang, Bangrong Cao
Summary: This study revealed the impact of EREG on EGFR-TKI sensitivity and its mechanisms in NSCLC, suggesting macrophage-produced EREG as a potential novel regulator and biomarker for EGFR-TKI therapy in NSCLC.
Article
Medicine, Research & Experimental
Suntae Kim, Jang Su Jeon, Yong June Choi, Ga Hee Baek, Sang Kyum Kim, Keon Wook Kang
Summary: The heterogeneity of glutamine metabolism in EGFR-TKI-resistant lung cancer cells was evaluated in this study. It was found that CB-839, a specific GLS inhibitor, can effectively inhibit glutamine metabolism and exert enhanced anti-proliferating effects on acquired EGFR-TKI-resistant lung cancer cells.
Article
Biochemical Research Methods
Guan-Yuan Chen, Sheng-Kai Liang, Yu-Feng Wei, Te- Weng, Kuan-Yu Chen
Summary: We developed a rapid method for measuring the concentrations of EGFR-TKIs in plasma and CSF using UHPLC-MS/MS. This method was validated and successfully applied in NSCLC patients. It helps predict the effectiveness and toxicities of EGFR-TKIs for lung cancer patients.
ANALYTICAL BIOCHEMISTRY
(2023)
Article
Oncology
J. Remon, B. Besse, S. Ponce Aix, A. Callejo, K. Al-Rabi, R. Bernabe, L. Greillier, M. Majem, N. Reguart, I. Monnet, S. Cousin, P. Garrido, G. Robinet, R. Garcia Campelo, A. Madroszyk, J. Mazieres, H. Curcio, B. Wasag, Y. Pretzenbacher, B. Fournier, A. -M. C. Dingemans, R. Dziadziuszko
Summary: The APPLE trial aimed to evaluate the feasibility of longitudinal plasma EGFR T790M monitoring for the best sequencing strategy of gefitinib and osimertinib. The results showed that serial monitoring of T790M mutation in advanced EGFR-mutant non-small-cell lung cancer was feasible, and molecular progression before RECIST PD led to an earlier switch to osimertinib with satisfactory progression-free survival and overall survival outcomes.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
Jingwei Li, Peiyi Li, Jun Shao, Shufan Liang, Yuntian Wan, Qiran Zhang, Changshu Li, Yalun Li, Chengdi Wang
Summary: This review summarizes the potential mechanisms of noncoding RNAs in EGFR TKI-resistant lung cancer and their clinical applications, and highlights the barriers that need to be addressed.
Article
Biochemistry & Molecular Biology
Lumei Dai, Feng Qin, Yuying Xie, Bin Zhang, Zhijie Zhang, Sijia Liang, Fujia Chen, Xiaochao Huang, Hengshan Wang
Summary: Dual- or multi-targeted EGFR inhibitors have the potential to overcome EGFR inhibitor resistance and have advantages over combination therapy. In this study, a series of 4-anilinoquinazoline derivatives were designed and synthesized as dual EGFR-DNA targeting anticancer agents. Compound 6g showed potent anticancer activity against H1975 cells and significantly inhibited the expression of p-EGFR and its downstream signaling molecules. Moreover, 6g efficiently inhibited tumor growth in a xenograft model without side effects.
BIOORGANIC CHEMISTRY
(2023)
Article
Oncology
Shun-Ichi Suzuki, Satoshi Matsusaka, Mitsuharu Hirai, Harumi Shibata, Koichi Takagi, Nobuyuki Mizunuma, Kiyohiko Hatake
INTERNATIONAL JOURNAL OF ONCOLOGY
(2015)
Article
Oncology
Kazuhisa Hosoya, Satoshi Matsusaka, Tomomi Kashiwada, Koichi Suzuki, Norio Ureshino, Akemi Sato, Yoshio Miki, Kazuki Kitera, Mitsuharu Hirai, Kiyohiko Hatake, Shinya Kimura, Naoko Sueoka-Aragane
PATHOLOGY & ONCOLOGY RESEARCH
(2017)
Article
Oncology
Tomomi Nakamura, Naomi Watanabe, Akemi Sato, Kazutoshi Komiya, Hitomi Umeguchi, Toshiya Hosomi, Mitsuharu Hirai, Eisaburo Sueoka, Shinya Kimura, Naoko Sueoka-Aragane
Article
Oncology
Tatsunori Shimoi, Akinobu Hamada, Marifu Yamagishi, Mitsuharu Hirai, Masayuki Yoshida, Tadaaki Nishikawa, Kazuki Sudo, Akihiko Shimomura, Emi Noguchi, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Takayuki Kinoshita, Takahiro Fukuda, Yasuhiro Fujiwara, Kenji Tamura
Article
Oncology
Satoshi Matsusaka, Masahiro Kozuka, Hidenori Takagi, Hiroshi Ito, Sayuri Minowa, Mitsuharu Hirai, Kiyohiko Hatake
Article
Oncology
Tomomi Nakamura, Naoko Sueoka-Aragane, Kentaro Iwanaga, Akemi Sato, Kazutoshi Komiya, Naomi Kobayashi, Shinichiro Hayashi, Toshiya Hosomi, Mitsuharu Hirai, Eisaburo Sueoka, Shinya Kimura
JOURNAL OF THORACIC ONCOLOGY
(2012)
Article
Oncology
Ruriko Tanaka, Junya Kuroda, William Stevenson, Eishi Ashihara, Takayuki Ishikawa, Tomohiko Taki, Yutaka Kobayashi, Yuri Kamitsuji, Eri Kawata, Miki Takeuchi, Yoshihide Murotani, Asumi Yokota, Mitsuharu Hirai, Satoshi Majima, Masafumi Taniwaki, Taira Maekawa, Shinya Kimura
Review
Chemistry, Analytical
Shun-ichi Suzuki, Mariko Komori, Mitsuharu Hirai, Norio Ureshino, Shinya Kimura
Article
Multidisciplinary Sciences
Tomomi Nakamura, Chiho Nakashima, Kazutoshi Komiya, Kazuki Kitera, Mitsuharu Hirai, Shinya Kimura, Naoko Aragane
Article
Biochemistry & Molecular Biology
Hidenori Takagi, Liang Dong, Morgan D. Kuczler, Kara Lombardo, Mitsuharu Hirai, Sarah R. Amend, Kenneth J. Pienta
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Endocrinology & Metabolism
Hiroyuki Fujimoto, Naotaka Fujita, Keita Hamamatsu, Takaaki Murakami, Yuji Nakamoto, Tsuneo Saga, Takayoshi Ishimori, Yoichi Shimizu, Hiroyuki Watanabe, Kohei Sano, Norio Harada, Hiroshi Nakamura, Kentaro Toyoda, Hiroyuki Kimura, Shunsaku Nakagawa, Mitsuharu Hirai, Atsushi Murakami, Masahiro Ono, Kaori Togashi, Hideo Saji, Nobuya Inagaki
Summary: A novel exendin-based probe labeled with fluorine-18 was developed for PET imaging of the pancreas in healthy male subjects, demonstrating safety and utility for non-invasive visualization. The mean standardized uptake value of the pancreas during PET scans was found to be higher than surrounding organs, with no serious adverse events observed.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Masahiro Kozuka, Francesca Battaglin, Priya Jayachandran, Jingyuan Wang, Hiroyuki Arai, Shivani Soni, Wu Zhang, Mitsuharu Hirai, Satoshi Matsusaka, Heinz-Josef Lenz
Summary: The study characterized CTCs in mCRC patients at the single-cell level using RNA sequencing, identifying that CTCs expressing EMT-related genes could have prognostic value in predicting patient outcomes.
Article
Hematology
Kunihito Arai, Masahiro Sakaguchi, Shunsuke Yui, Tomoaki Kitano, Miho Miyata, Mayumi Yogosawa, Kazutaka Nakayama, Kenji Tajika, Kensuke Usuki, Junya Kuroda, Nobuhiko Uoshima, Yutaka Kobayashi, Hitoji Uchiyama, Yasushi Kubota, Shinya Kimura, Shinichiro Mori, Mitsuharu Hirai, Satoshi Wakita, Hiroki Yamaguchi
Summary: This study evaluates the sensitivity and specificity of i-densy IS-5320 gene analyzer in the simultaneous detection of MPN-associated gene mutations. The results show that i-densy IS-5320 exhibits high accuracy in detecting JAK2 V617F, JAK2 exon 12, CALR, and MPL mutations, with detection accuracies ranging from 99.7% to 100.0%. There is a strong positive correlation between the JAK2 V617F allele burden measured using conventional methods and i-densy IS-5320.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2022)
Article
Biochemical Research Methods
Soo Hyeon Kim, Hiroshi Ito, Masahiro Kozuka, Hidenori Takagi, Mitsuharu Hirai, Teruo Fujii